Yuan-Siang Lui

Scientist (Formulation Development, Vaccines) at Hilleman Laboratories Singapore Pte Ltd
  • Claim this Profile
Contact Information
Location
Singapore, SG

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Scientist (Formulation Development, Vaccines)
      • Jul 2021 - Present

      1) Establishing first-of-its-kind Fill-and-Finish (Aseptic Filling) production line in cGMP facility. 2) Developing novel formulations (i.e. vaccine lyophilized and liquid formulation etc) to tackle the high disease burden of preventable diseases in developing countries. 3) Analytical development and method qualification to ensure success in drug substance and drug product development. 4) Supporting master cell bank and working cell bank generation. 5) Performing technology transfer (including coming out with technology transfer plan, protocol and after action review report) Show less

    • France
    • Food and Beverage Manufacturing
    • 700 & Above Employee
    • Pharmaceutical Scientist
      • May 2019 - Jul 2021

      Achievements: 1) 3 patents on Oral Drug Delivery and Wound Healing technologies, capable of achieving controlled release and solubility enhancement 2) Established international collaborations on Personalized Medication technology development. Experiences: 1) Skilled in design of experiments (DoE) for formulation development and process optimization, to fabricate oral dosage forms such as immediate release, controlled release, gastroretentive, tab-in-tab and orodispersible tablets/films. 2) Experienced in physico-chemical characterizations of API and excipients, such as powder flow assessment, polymorphism determination, solubility evaluation, etc. 3) Worked with international and cross-functional teams involving marketing, IP, legal and customer care to devise a product launch strategy and deliver product development milestones. 4) Collaborated with multinational partners to address unmet difficulties in multidisciplinary projects (e.g. amorphous solid dispersion formulation and co-processed excipients development). Show less

    • Singapore
    • Hospitals and Health Care
    • 700 & Above Employee
    • Research Fellow
      • Dec 2017 - May 2019

      Achievements: 1) 1 patent on novel bioink for human meniscus implant Experiences: 1) Constructed 3D-printed implants with biomimicry designs and optimal biomechanical properties using novel bioink 2) Experienced with pre-clinical trial for implants evaluation 3) Familiar with regulatory guidelines on product manufacturing and registration Achievements: 1) 1 patent on novel bioink for human meniscus implant Experiences: 1) Constructed 3D-printed implants with biomimicry designs and optimal biomechanical properties using novel bioink 2) Experienced with pre-clinical trial for implants evaluation 3) Familiar with regulatory guidelines on product manufacturing and registration

    • Singapore
    • Higher Education
    • 700 & Above Employee
    • Research Fellow
      • Jan 2016 - Dec 2017

      Achievements: 1) Sustained release technology platform development, for delivery of Ranibizumab, NSAIDs, and peptides. 2) Pharmacokinetics analysis for dual-drug loaded peripheral arterial stent in swine model - Formulated sustained-release liposomal formulations to address restenosis after stenting - Developed in-house in vivo pharmacokinetic analysis from swine’s blood and artery tissues using LCMS technique 3) In vivo toxicology evaluation in rat model with Kv1.3 inhibitor PAP-1 peptide for dry eye disease - Achieved peptide liposomal delivery to inhibit potassium channel of effector memory TEM cells in rat model - Performed in vivo toxicology testing and formulation efficacy evaluation using LCMS pharmacokinetic analysis Show less

    • United States
    • Higher Education
    • 700 & Above Employee
    • Visiting Scientist
      • Jul 2017 - Aug 2017

      Developed primary human hepatocytes and hepatic stellate cells co-culture system as in vitro drug screening platform Developed primary human hepatocytes and hepatic stellate cells co-culture system as in vitro drug screening platform

    • United Kingdom
    • Higher Education
    • 700 & Above Employee
    • Overseas Research Student
      • Aug 2014 - Jul 2015

      Achievement: Technology disclosure on dual growth factor/NSAID release from musculoskeletal implants Experiences: 1) Tri-culture pre-clinical musculoskeletal model development 2) Growth factor and small molecules API sustained release system development Achievement: Technology disclosure on dual growth factor/NSAID release from musculoskeletal implants Experiences: 1) Tri-culture pre-clinical musculoskeletal model development 2) Growth factor and small molecules API sustained release system development

Education

  • Loughborough University
    Doctor of Philosophy - PhD
    2012 - 2016
  • Nanyang Technological University
    Doctor of Philosophy - PhD, Materials Engineering
    2012 - 2016
  • Nanyang Technological University
    Bachelor of Engineering - BE, Materials Science
    2007 - 2011
  • Nanyang Technological University
    Doctor of Philosophy - PhD

Community

You need to have a working account to view this content. Click here to join now